Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

miro healthcare limited - brinzolamide 10 mg/ml - eye drops, suspension - 1 % - active: brinzolamide 10 mg/ml excipient: benzalkonium chloride carbomer disodium edetate dihydrate hydrochloric acid mannitol sodium chloride sodium hydroxide tyloxapol water for injection - decrease in intraocular pressure in ocular hypertension and open angle glaucoma.

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - brinzolamide - eye drops - 10mg/1ml

Соединенные Штаты - английский - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515), brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - simbrinza (brinzolamide and brimonidine tartrate ophthalmic suspension) 1% and 0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. simbrinza is contraindicated in patients who are hypersensitive to any component of this product. simbrinza is contraindicated in neonates and infants (under the age of two years) [see use in specific populations (8.4)] . pregnancy category c: developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/k

Израиль - английский - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops, suspension - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Израиль - английский - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - eye drops suspension - brimonidine tartrate 2 mg / 1 ml; brinzolamide 10 mg / 1 ml - brinzolamide, combinations - decrease of elevated intraocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Европейский союз - английский - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide - glaucoma, open-angle; ocular hypertension - ophthalmologicals - azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

Израиль - английский - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - ophthalmic suspension - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - brinzolamide 10 mg/ml (a 2% overage is applied during manufacture);  ; timolol maleate 6.8 mg/ml equivalent to 5 mg/ml (0.5%) timolol as free base;   - eye drops, suspension - 1%/0.5% - active: brinzolamide 10 mg/ml (a 2% overage is applied during manufacture)   timolol maleate 6.8 mg/ml equivalent to 5 mg/ml (0.5%) timolol as free base   excipient: benzalkonium chloride carbomer disodium edetate hydrochloric acid mannitol purified water sodium chloride sodium hydroxide tyloxapol - azarga is indicated for the decrease of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension for whom monotherapy with either component provides insufficient iop reduction

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brinzolamide, quantity: 10 mg/ml - eye drops - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; tyloxapol; mannitol; carbomer 974p; hydrochloric acid; sodium hydroxide; purified water - brinzoquin eye drops 1.0% are indicated to decrease intraocular pressue in: ocular hypertension & open-angle glaucoma.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brinzolamide, quantity: 10 mg/ml - eye drops - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; tyloxapol; mannitol; carbomer 974p; hydrochloric acid; sodium hydroxide; purified water - azopt 1.0% eye drops are indicated to decrease intraocular pressure in : ocular hypertension; open-angle glaucoma.